This is the authors' abstract. We don't add key points for this paper.
Immune thrombocytopenia (ITP) in adults is a chronic disease resulting from increased platelet destruction and impaired platelet production. Splenectomy remains the most effective and durable treatment in cases that are refractory to first-line therapy, but its use has declined because of the availability of alternate medical therapy, the associated risk of infection, and concern for surgery-related complications. Rituximab (Rituxan) may be an effective alternative but carries the risk of immunosuppression.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Thota et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: